| Select Urgent Care Llc | |
|
14884 Kirkwood Dr Baxter MN 56425-8451 | |
| (218) 824-5027 | |
| Not Available |
| Full Name | Select Urgent Care Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 14884 Kirkwood Dr, Baxter, Minnesota |
| Authorized Official Name and Position | Trevor Harting (OWNER) |
| Authorized Official Contact | 2188245027 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Select Urgent Care Llc 14884 Kirkwood Dr Baxter MN 56425-8451 Ph: (218) 824-5027 | Select Urgent Care Llc 14884 Kirkwood Dr Baxter MN 56425-8451 Ph: (218) 824-5027 |
| NPI Number | 1952063158 |
|---|---|
| Provider Enumeration Date | 10/06/2021 |
| Last Update Date | 11/13/2023 |
| Medicare PECOS PAC ID | 1658762646 |
|---|---|
| Medicare Enrollment ID | O20211230000768 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952063158 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| 261QU0200X | Clinic/center - Urgent Care | (* (Not Available)) | Secondary |
| Provider Name | Trevor L Harting |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386691210 PECOS PAC ID: 3476546458 Enrollment ID: I20040406000415 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Esther Doele |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730191990 PECOS PAC ID: 6800811332 Enrollment ID: I20051013000177 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Georgeanna D Knutson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811080104 PECOS PAC ID: 2961401005 Enrollment ID: I20061219000047 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Jessica Anne Fligge |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811195985 PECOS PAC ID: 7517029408 Enrollment ID: I20081231000416 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Sarah A Lundy |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699923185 PECOS PAC ID: 3476697210 Enrollment ID: I20100217000888 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Trisha Marie Rau |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063762953 PECOS PAC ID: 4183876105 Enrollment ID: I20121219000582 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Tracy A Roehl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043563463 PECOS PAC ID: 2264686823 Enrollment ID: I20130206000465 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Amber D Rossin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518368133 PECOS PAC ID: 7719209865 Enrollment ID: I20141201001671 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Brett J Kramer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1477952398 PECOS PAC ID: 4082937081 Enrollment ID: I20141224000470 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Sara Carlson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649668492 PECOS PAC ID: 1052622321 Enrollment ID: I20150612002455 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Emily Jl Deno |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649638727 PECOS PAC ID: 2365731148 Enrollment ID: I20160518000418 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Elizabeth J Mclean |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043668494 PECOS PAC ID: 8729373311 Enrollment ID: I20160822001056 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Rebecca Dewolf |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386299329 PECOS PAC ID: 8123359007 Enrollment ID: I20191007003038 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Ammber Sahr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225639230 PECOS PAC ID: 7719399559 Enrollment ID: I20201218001389 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Lora C Martinson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811573942 PECOS PAC ID: 0547677056 Enrollment ID: I20210330001499 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Abigail Ann Baillif |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295305662 PECOS PAC ID: 8729483946 Enrollment ID: I20210825002761 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Sarah Jean White |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518692789 PECOS PAC ID: 2062882335 Enrollment ID: I20221230002086 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Destiny Brianne Amundson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326765892 PECOS PAC ID: 4284005539 Enrollment ID: I20230124001439 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Madison Mackenzie Kramer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871275982 PECOS PAC ID: 5799148367 Enrollment ID: I20230830000171 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
| Provider Name | Kimberly Nan Palkert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164205621 PECOS PAC ID: 8123473352 Enrollment ID: I20231009001308 |
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
News Archive
When prenatal diagnosis detects the severe heart defect hypoplastic left heart syndrome (HLHS) in a fetus, a comprehensive prenatal evaluation is important to provide parents an accurate prognosis. In HLHS, one of the heart's pumping chambers is severely underdeveloped. However, say researchers, in two-thirds of cases, reconstructive surgery affords the infant an excellent chance of early survival.
ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity.
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
› Verified 6 days ago
Essentia Health-st Joseph's Baxter Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13060 Isle Drive, Baxter, MN 56425 Phone: 218-828-2880 | |
Dermatology Professionals Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15167 Edgewood Dr, Suite 200, Baxter, MN 56401 Phone: 218-454-7546 | |
True North Counseling And Consulting Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13432 Elmwood Dr Ste 209, Baxter, MN 56425 Phone: 218-839-9421 | |
Centracare - Baxter Specialty Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7418 Forthun Rd, Baxter, MN 56425 Phone: 320-251-2700 | |
Essentia Health - Baxter Specialty Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13060 Isle Drive, Baxter, MN 56425 Phone: 218-828-2880 | |
Dermatology Professionals, Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 13359 Isle Dr, Ste 3, Baxter, MN 56425 Phone: 218-454-7546 | |
Aim-axness Integrative Medicine, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 7350 Clearwater Rd, Baxter, MN 56425 Phone: 218-454-5050 |